今年发表在Cancer cell 杂志上的一篇名为:Neoantigen-specific CD4 T cells in human melanoma have diverse differentiation states and correlate with CD8 T cell, macrophage, and B cell function,则是针对新抗原的CD4 T细胞,包括MHC-II类的致癌驱动突变,也在癌症患者中被发现。在这项研究中作者发现,新抗原特异...
同样是今年,在Nature Cancer杂志上发表了另一篇一篇名为“The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response”的文章,首次证实了CXCL13+ T细胞可以通过和树突细胞(DC)相互作用来发挥重要的抗肿瘤功能。这项研究的作者通过单细胞测序...
作者发现在非小细胞肺癌中,治疗前肿瘤内的CXCL13+肿瘤反应性CD8 T细胞主要由terminally differentiated T cells构成,而治疗后precursor-like T cells增加。在皮肤细胞癌中terminally differentiated T cells一直占据统治地位。而在乳腺癌中现象因治疗方式而异,只用anti-PD-1的cohort 1一直是terminally differentiated T cell...
在他们的荟萃分析中对CD4+ T细胞池进行剖析,作者发现CXCL13+ CD4+ T细胞表现出1型辅助T细胞样状态,表达IFNG和IL21等效应分子,以及PDCD1、HAVCR2、TIGIT和TOX等衰竭标志物,这与之前的观察一致,表明这些细胞可能在肿瘤中积极看到抗原。与其...
CD4+ T细胞在接受免疫治疗后的动态变化表明,CXCL13+ CD4+ T细胞在响应性肿瘤中显著增加,且其丰度与治疗反应显著相关。同时,联合测量CXCL13+ CD4+ 和CXCL13+ CD8+ T细胞的丰度可能提供了更准确的免疫治疗响应预测。 四、结论与展望 本研究通过深入分析CXCL13+ T细胞在ICB治疗中的动态变化和功能,为优化免疫治疗策略...
CXCL13-producing PD-1hiCXCR5CD4 T cells were discovered in synovial tissues of rheumatoid arthritis (RA). Further intensive analysis of RA samples led to the proposal of PD-1hiCXCR5CD4 T cells as a pathogenic CD4 subset, peripheral helper T (Tph) cells. Tph cells are upregulated also in ...
CD4+ T cells are critical regulators of immune responses but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce a comprehensive image of CD4+ T cells infiltrating breast tumors (TIL) using limited ex vivo manipulation to better understand ...
与其他CD4+T细胞亚群相比,CXCL13+CD4+T细胞在ICB后反应的肿瘤中比无反应的肿瘤增加。值得注意的是,对基线CXCL13+ CD4+和CD8+ T细胞的联合评估在预测ICB反应性方面达到了≥90%的高准确率,这表明肿瘤特异性CD4+和CD8+ T细胞都可能对ICB反应有所贡献。
当肿瘤微环境整体免疫抑制强度较低时，ICB 有效阻断了肿瘤特异性 CXCL13+CD8+ T 细胞前体细胞向耗竭程度较高的终末状态的分化（图3）。图3：CXCL13+CD8+ T细胞亚型与ICB治疗关系 在 CD4 T 细胞中，ICB 显著地增加了 CXCL13+CD4+ T 细胞（图4），表明了该类群是 CD4 T 细胞中对 ICB 响应的主要类群，这...
a-c, Comparison of the frequency of Tregs (a), other Th (b) and naïve (c) CD4 T cells in all CD4 T cells from pre- and post-treatment responsive and non-responsive tumors. Data were summarized from n = 20, 15, 22, 7, 53, 22, 12, 4 and 7 tumor samples from datasets...